CHTP

Chelsea Therapeutics Reports Significant Reduction in Severity of Symptoms During Titration Phase of Pivotal Droxidopa Study in Neurogenic Orthostatic Hypotension - 11/03 - 07:01 AM ET

Chelsea Therapeutics to Present At the Rodman and Renshaw 10th Annual Healthcare Conference On Monday, November 10, 2008 - 10/30 - 07:31 AM ET

Chelsea completes enrollment for Phase II arthritis trial - 10/30 - 04:45 AM ET

Data From Chelsea Therapeutics' Phase III Trial of Droxidopa in Neurogenic Orthostatic Hypotension to be Presented at 19th Annual International Symposium on the Autonomic Nervous System - 10/29 - 07:25 AM ET

CHTP: Completes Enrollment for Ph II Trial of CH-1504 in Rheumatoid Arthritis - 10/28 - 09:15 AM ET

Chelsea Therapeutics Completes Enrollment in Phase II Trial of CH-1504 in Rheumatoid Arthritis - 10/28 - 07:25 AM ET

Chelsea Therapeutics to Host Conference Call to Discuss Third Quarter 2008 Results - 10/27 - 07:30 AM ET

Chelsea Therapeutics wins DSMB positive review for Phase II arthritis study - 10/22 - 08:35 AM ET

Chelsea Therapeutics Announces Positive DSMB Recommendation for CH-1504 Phase II Trial in Rheumatoid Arthritis - 10/21 - 07:30 AM ET

Page 1 of 4 1 2 3 4 Previous | Next

<< Back to Stock Index

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.